

VENMAX
DRUGS AND PHARMACEUTICALS LIMITED

To,
The Secretary,
BSBI Limited,
Phiroze Jeejeebhoy,
Towers, Dalal Street,
Fort, Mumbai - 400 001.

Date: 28.03.2022

scrip code: 531015

Dear Sir/Madam,

Sub: Unaudited Financial Results for the Quarter ended 30th June, 2021:

Pursuant to Reg.30 and 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that the Board of Directors of the Company at its meeting held on 28.03.2022 has approved the following:

- (i) Approved the Un-Audited financial results of the Company for the quarter ended 30th June, 2021 and Limited Review Report of the Auditors thereon.

This is for your information and record.

Thanking you,

Yours Faithfully,

For Venmax Drugs and Pharmaceuticals Limited

Nooka
Krishnaiah
N. Krishnaiah
Director
DIN:07279009





Independent Auditor's Report on Quarterly Unaudited financial Results of M/s VENMAX DRUGS AND PHARMACEUTICALS LIMITED pursuant to Regulation 33 of the SEBI(Listing and Obligations and Disclosure requirements) Regulations, 2015.

To the Board of Directors of **VENMAX DRUGS AND PHARMACEUTICALS LIMITED**

We have reviewed the accompanying statement of unaudited financial results of **VENMAX DRUGS AND PHARMACEUTICALS LIMITED** ('The Company') for the quarter ended June 30, 2021. This statement is the responsibility of the company's management and has been approved by the board of directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review of the Statement in accordance with the Standards on Review Engagement (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity' issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial results are free from material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly we do not express an audit opinion.

Based on our review conducted as stated above, nothing has come to our attention that causes us to believe that the accompanying statement, prepared in accordance with the recognition and measurement principles laid down in the applicable Indian accounting standards specified under section 133 of the Companies Act, 2013, read with relevant rules issued there under and other recognized accounting principles and policies has not disclosed the information required to be disclosed in terms of the regulation 33 of the SEBI (Listing Obligations and disclosure requirements) regulations, 2015 including the manner in which it is to be disclosed or that it contains any material misstatements.

For **NSVR & Associates LLP**

Chartered Accountants

FRN: 008801S/S200067


Suresh Gannamani

Partner

Membership No.226870

UDIN: 22226870ANQJUK3778



Place: Hyderabad

Date: 28/05/2022

**VENMAX DRUGS AND
(CIN: L2423)
Extract of Un-audited financial**

PHARMACEUTICALS LIMITED

60TG1988PLC009102)

results for the Quarter Ended 30.06.2021

	Quarter ended	Quarter ended	Quarter ended	Year ended
	30.06.2021	31.03.2021	30.06.2020	31.03.2021
	Un-Audited	Audited	Un-Audited	Audited
Total income				
Net Profit (before Tax, Exceptional and/or Extraordinary items)				
Net Profit before tax (after Exceptional and/or Extraordinary items)				
Net Profit after tax (after Exceptional and/or Extraordinary items)	0.00	18.14	6.95	34.93
Total Comprehensive Income [Comprising Profit after tax and Other Comprehensive Income (after tax)]	(3.41)	3.10	(6.53)	(16.18)
	(3.41)	3.10	(6.53)	(16.18)
	(3.42)	3.08	(6.55)	(16.25)
paid up Equity Share Capital (Rs.10/- Per Equity Share)				
Reserves (excluding Revaluation Reserve as shown in the Balance Sheet)	(3.42)	3.08	(6.55)	(16.25)
Earnings Per Share (of Rs.10/- each) (Not Annualised):				
a) Basic	523.89	523.89	523.89	523.89
b) Diluted	-	-	-	(786.28)
The above Financial results as recommended by the Audit Committee with effect from 1st January 2021	-0.07	0.06	-0.12	-0.31
	-0.07	0.06	-0.12	-0.31

The above Financial results as recommended by the Audit Committee will be discussed at the meeting on July 2021.

Note : The above is an extract of the detailed format of Quarterly Financial Statements and Other Disclosure Requirements Regulations, 2015. The full format of the Regulations is available on the website of the Securities and Exchange Board of India (SEBI) at www.sebi.gov.in and www.bseindia.com.

Place : Hyderabad
Date : 19/07/2021

For Venmax[®] Drugs and Pharmaceuticals Limited

Raj Kumar Rai
Managing Director
DIN: 0009207

DIN: 0009207

DIN: 0009207

